AllianceRx Walgreens Pharmacy, Total Care Rx Chosen to Distribute to Hyftor

Hyftor was approved in April 2022 to treat patients with the rare disease facial angiofibroma associated with tuberous sclerosis complex.

Nobelpharma America has chosen AllianceRx Walgreens Pharmacy and Total Care Rx to distribute Hyftor (sirolimus) topical gel, which is approved to treat patients six years and older with facial angiofibroma associated with tuberous sclerosis complex. The FDA approved Hyftor in April 2022, and Hyftor has orphan drug status for this indication.

Tuberous sclerosis complex is a genetic disorder that causes tumors to form in various organs, primarily the brain, eyes, heart, kidneys, skin, and lungs. Facial angiofibroma is seen in about 75% to 80% of tuberous sclerosis complex patients. Angiofibroma commonly presents as small, red or pink bumps on the face. In the United States, about 50,000 people have tuberous sclerosis complex, and an estimated 40,000 have TSC-related facial angiofibroma, with most diagnosed as children.

The retail price of Hyftor is as low as $1,730.40 for one tube, according to GoodRx.

Nobelpharma has recently launched Nobelpharma Connect, a hub where patients may learn about eligibility and enrollment in access programs including assistance program, copay program, and other support services.

“Nobelpharma is committed to advancing the scientific understanding of TSC and delivering new options to individuals and families impacted by this disease,” Yoshiki Kida, president and CEO of Nobelpharma America, said in a press release. “As we introduce Hyftor, we look forward to strengthening our relationships within the patient community, maintaining a dialogue and listening to their experiences to help shape the future of research and treatment.